Accepted for Publication: April 19, 2013.
Published Online: July 22, 2013. doi:10.1001/jamaneurol.2013.3216.
Acquisition of data: All authors.
Analysis and interpretation of data: Kayser, Titulaer, Dalmau.
Drafting of the manuscript: All authors.
Critical revision of the manuscript for important intellectual content: Kayser, Titulaer, Dalmau.
Statistical analysis: Kayser, Titulaer, Dalmau.
Obtained funding: Kayser, Dalmau.
Administrative, technical, and material support: Titulaer, Gresa-Arribas, Dalmau.
Study supervision: Dalmau.
Conflict of Interest Disclosures: Dalmau receives royalties from Athena Diagnostics for a patent for the use of Ma2 as an autoantibody test and licensing fees from Euroimmun for a patent for the use of NMDAR as an autoantibody test.
Funding/Support: This work was supported by grants R25-MH060490 (Kayser), R01 NS077851 (Dalmau), and R01 MH094741 (Dalmau) from the National Institutes of Health, KWF fellowship 2009-4451 from the Dutch Cancer Society (Titulaer), and PI11/01780 from the Fondo de Investigaciones Sanitarias (Dalmau) and by Fundació la Marató TV3 (Dalmau).
Role of the Sponsors: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.
Additional Contributions: One MRI was courtesy of Dr Paul W. Wirtz, Department of Neurology, Haga Teaching Hospital, the Hague, the Netherlands. We thank all physicians, patients, and families who provided clinical information.